FDA Grants Orphan Drug Status To Reata's RTA 402 For Treatment Of Pancreatic Cancer
"Pancreatic cancer is a devastating disease with few effective therapies," said Warren Huff, CEO of Reata. "We are encouraged by the initial results with RTA 402 in pancreatic cancer, and are pleased that the FDA has recognized this potential by granting Orphan Drug status."
FDA's Orphan Drug Act was designed to encourage the development of products that demonstrate promise for the diagnosis, prevention and/or treatment of life-threatening or very serious conditions affecting 200,000 persons or less in the United States. Orphan drug designation provides an important economic incentive for the development of new products in the cancer field. U.S. orphan drug designation provides for seven years of market exclusivity, reduction in regulatory fees, and additional regulatory support for R&D initiatives.
About RTA 402
RTA 402 is an orally available, first-in-class Antioxidant Inflammation Modulator (AIM). RTA 402 and others AIMs work via a novel mechanism that promotes the resolution of inflammation and oxidative stress that underlie many intractable diseases, including cancer and renal/cardiovascular disease. Earlier this year, Phase 1 results with RTA 402 were presented at the Annual Meeting of the American Society of Clinical Oncology. The drug was shown to be well tolerated; to have single agent anti-cancer activity including multiple Objective Responses; to modulate target biological pathways including Nrf2, NF-kappaB, and STAT3; and to reduce levels of pro-inflammatory cytokines including TNF and VEGF. RTA 402 is currently in mid-stage clinical testing for pancreatic cancer and chronic kidney disease.
Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases. The company's lead program is in advanced clinical trials for chronic kidney disease and cancer. In parallel with its clinical development, Reata is advancing a breakthrough drug discovery platform based around the use of small molecule molecular chaperones to correct protein misfolding. Reata takes a new and different approach to biotechnology, managing its pipeline as a portfolio of opportunities that can be advanced on a single management and physical infrastructure, streamlining the route to human trials and approval. Founded in 2002, Reata is based in the Dallas area. For more information, visit http://www.reatapharma.com.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
Reata. "FDA Grants Orphan Drug Status To Reata's RTA 402 For Treatment Of Pancreatic Cancer." Medical News Today. MediLexicon, Intl., 16 Oct. 2008. Web.
29 Apr. 2017. <http://www.medicalnewstoday.com/releases/125718.php>
Reata. (2008, October 16). "FDA Grants Orphan Drug Status To Reata's RTA 402 For Treatment Of Pancreatic Cancer." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.